Tyra Biosciences has announced new data showing that its investigational therapy, TYRA-300, improves bone growth and corrects skeletal abnormalities in preclinical models of achondroplasia and hypochondroplasia.
Tyra Biosciences has released new preclinical findings supporting the potential of its investigational therapy, TYRA-300, as a treatment for skeletal dysplasia caused by FGFR3 mutations, including achondroplasia (ACH) and hypochondroplasia (HCH). The data, generated using disease-relevant mouse models, suggest that TYRA-300 could help address the underlying biological dysfunction responsible for these disorders, offering hope for improved treatment options.
Achondroplasia, the most common form of dwarfism, and its milder counterpart hypochondroplasia are both caused by activating mutations in…